Clinical trials
Metastatic Soft Tissue Sarcoma clinical trials
Below are recruiting metastatic soft tissue sarcoma clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT02275286RecruitingPhase 1/Phase 2
Trabectedin plus radiation for select soft tissue sarcomas
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
BordeauxAges 18 years+ - NCT05961761RecruitingPhase 2
Testing propranolol plus pembrolizumab for advanced sarcoma
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
AarhusAges 18 years+ - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT06074692RecruitingPhase 2
PARP inhibitor, SBRT, and immunotherapy for advanced sarcoma
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 10–70 - NCT07741877RecruitingPhase 2
Immune cells for advanced soft tissue sarcoma
This trial tests a treatment made from your own immune cells, called tumor-infiltrating lymphocytes, to see if they can shrink or slow down advanced soft tissue sarcoma. It might be an option if you have tried other treatments and your cancer is still growing.
Tampa, FloridaAges 16–70 - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06669013RecruitingPhase 3
Chemo-immunotherapy for young people with bone or soft tissue sarcoma
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
Saint PetersburgAges Up to 18 years - NCT07628634RecruitingEarly Phase 1
Testing a Low-Methionine Diet in Solid Tumor Patients
This early-stage study explores whether eating a diet low in methionine (a natural amino acid found in protein) might help people with advanced solid tumors. Researchers will track how this dietary change affects blood levels and may improve treatment outcomes alongside standard cancer care.
Orange, CaliforniaAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT07615049RecruitingPhase 3
Shorter versus standard radiation for soft tissue sarcoma
This trial compares a shorter course of radiation therapy with the standard longer course for people with soft tissue sarcoma in an arm or leg. The goal is to see if the shorter course works just as well and may be more convenient.
Birmingham, AlabamaAges 18 years+ - NCT07507773RecruitingPhase 2
Radiation before surgery for limb or trunk wall sarcoma
This trial tests a shorter course of radiation given before surgery for soft tissue sarcoma in the arms, legs, or trunk wall. It aims to see if this approach works well long-term and may help you keep your limb.
LilleAges 18 years+ - NCT07460986RecruitingPhase 1/Phase 2
Bexmarilimab plus doxorubicin for advanced soft-tissue sarcoma
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
BadalonaAges 18 years+ - NCT06805669Recruiting
Early palliative care for advanced soft tissue sarcoma
This study tests whether adding palliative care early on to standard cancer treatment improves quality of life for people newly diagnosed with advanced or metastatic soft tissue sarcoma.
Toronto, OntarioAges 18 years+ - NCT07436364RecruitingEarly Phase 1
Ultrasound to monitor sarcoma response to radiation
This trial uses contrast-enhanced ultrasound to see how well soft tissue sarcoma responds to radiation therapy given before surgery. The goal is to find out if this imaging method can help doctors assess treatment effects earlier.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07432932Recruiting
Personalized treatment before surgery for high-risk sarcoma
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
LondonAges 18 years+ - NCT03138161RecruitingPhase 1/Phase 2
Testing three medicines for previously treated soft-tissue sarcoma
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
Santa Monica, CaliforniaAges 18 years+ - NCT04535271RecruitingPhase 2
Trabectedin, gemcitabine, and dacarbazine for advanced leiomyosarcoma
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
Santa Monica, CaliforniaAges 18 years+ - NCT07291297RecruitingPhase 2
Metformin plus standard therapy for soft tissue sarcoma
This trial tests adding metformin, a common diabetes drug, to the usual first cancer treatment for advanced soft tissue sarcoma. It may help the standard therapy work better.
Charlotte, North CarolinaAges 18 years+ - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT06873685Recruiting
Soft tissue sarcoma: surgery, rehab, and nutrition study
This trial is for people with a newly diagnosed soft tissue sarcoma that has not spread. It will study how surgery, physical therapy, and nutrition affect your recovery and quality of life.
Rome, LazioAges 18 years+ - NCT07173972RecruitingPhase 2
Proton radiation for inoperable soft tissue sarcoma
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
BergenAges 18 years+ - NCT07066982RecruitingPhase 1/Phase 2
CAR T cells targeting CD146 and HER2 for advanced sarcomas
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Beijing, Beijing MunicipalityAges 21–90
Hear when a new Metastatic Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic Soft Tissue Sarcoma trials by city
Studies with a site in or near these metro areas.
Metastatic Soft Tissue Sarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic soft tissue sarcoma?
- Yes. Clin2 currently lists 85 recruiting metastatic soft tissue sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic soft tissue sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic soft tissue sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.